Navigation Links
Accuray Announces Results for First Quarter Fiscal 2012
Date:11/8/2011

by calling 1-888-286-8010 (USA) or +1-617-801-6888 (International), Conference ID: 47941705, beginning at 5:00 p.m. PST / 8:00 p.m. EST, November 8, 2011 and will be available through November 22, 2011. A webcast replay will also be available from the Investor Relations section of the company's website at www.accuray.com from approximately 5:00 p.m. PST / 8:00 p.m. EST today through Accuray's release of its results for the second quarter of fiscal 2012, ending December 31, 2011.  

About AccurayAccuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the company's technologies and more than 598 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor StatementThe foregoing may contain certain forward-looking statements that involve risks and uncertainties, including those concerning Accuray's expectations about revenue for fiscal year 2012, the portion of revenue attributable to product revenue, profitability, gross margins, shipments and installations and backlog. Except for the historical information contained herein, the matters set forth in this press release, including Accuray's expectations about revenue for fiscal year 2012 are forward-looking statement
'/>"/>

SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Accuray Announces Results for the Fourth Quarter and Fiscal Year End 2008
2. Accuray Incorporated to Host Investor and Analyst Meeting at ASTRO
3. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
4. Accuray Reschedules Announcement of Results for First Quarter of Fiscal 2009
5. Accuray Postpones Release of First Quarter Fiscal 2009 Results
6. Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide
7. Accuray Incorporateds CEO to Speak at 27th Annual JP Morgan Healthcare Conference
8. Accuray Incorporated to Report Second Quarter Fiscal Year 2009 Financial Results
9. 10 Percent of U.S. Installed Base Signs on to Use Accuray Treatment Planning Service
10. Accuray to Showcase CyberKnife Treatment Planning Capabilities at Preeminent Radiation Oncology Conference
11. Accuray Incorporated to Present at Robert Baird 2009 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... 2015   GenoSpace , a precision medicine software company that ... broad use of genomic, imaging and other biomedical data in ... Michelle Munson , CEO of Aspera, an IBM Company, to ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... , , SAN FRANCISCO , Feb. ... ) acted as a placement agent in GenVec, Inc.,s (Nasdaq: ... shares of common stock, and warrants to purchase 4.2 million shares ... , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO ) , "We have been working with ...
... ... for Manufacture and Testing of Drug Products Imported to the European Union. ... Toronto, Ontario (PRWEB) ... to leading pharmaceutical companies, today announced successful completion of its recent Health Canada audit. ...
... , FORT LAUDERDALE, Fla. , ... published in EuroIntervention (EuroIntervention, 2010; 5:698-702) demonstrated ... and no late stent thrombosis at one year in ... percutaneous coronary intervention (PCI) and implantation of the company,s ...
Cached Biology Technology:Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 2Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 3Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 4Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 5Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 6Merriman Curhan Ford Acted as Placement Agent in GenVec's $28 Million Registered Offering 7Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 2Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 3OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 2OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Good Safety and Clinical Outcomes in Patients with Primary PCI for STEMI 3
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., the ... study that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four hundred years ... as a meeting place for peoples from different continents. This ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Infection with West Nile virus (WNV) causes no symptoms ... encephalitis. What determines the outcome of infection with WNV in ... and colleagues, at the Blood Systems Research Institute, San Francisco, ... (immune cells that suppress the function of other immune cells) ...
... New Orleans, LA Dr. John England, Professor and ... analyzed research findings and was responsible for the quality and ... resulting in new guidelines for treating Lou Gehrig,s disease, or ... the October 13, 2009 issue of Neurology , the ...
... target to stem biodiversity loss by next year, according to ... to biodiversity science. The goal was agreed at ... Biological Diversity in April 2003. Some 123 world ministers ... current rate of biodiversity loss at the local, national and ...
Cached Biology News:LSUHSC's England plays key role in developing new ALS treatment guidelines 2World will miss 2010 target to stem biodiversity loss, experts say 2World will miss 2010 target to stem biodiversity loss, experts say 3World will miss 2010 target to stem biodiversity loss, experts say 4World will miss 2010 target to stem biodiversity loss, experts say 5World will miss 2010 target to stem biodiversity loss, experts say 6
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
Automated Cell Culture Flask...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: